- Home
- KMT vs BEAM Comparison
KMT vs BEAM Comparison
Compare KMT & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KMT
- BEAM
- Stock Information
- Founded
- KMT 1938
- BEAM 2017
- Country
- KMT United States
- BEAM United States
- Employees
- KMT N/A
- BEAM N/A
- Industry
- KMT Industrial Machinery/Components
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KMT Industrials
- BEAM Health Care
- Exchange
- KMT Nasdaq
- BEAM Nasdaq
- Market Cap
- KMT 1.9B
- BEAM 1.9B
- IPO Year
- KMT N/A
- BEAM 2020
- Fundamental
- Price
- KMT $24.28
- BEAM $23.44
- Analyst Decision
- KMT Hold
- BEAM Buy
- Analyst Count
- KMT 6
- BEAM 10
- Target Price
- KMT $27.67
- BEAM $47.67
- AVG Volume (30 Days)
- KMT 993.2K
- BEAM 1.3M
- Earning Date
- KMT 02-05-2025
- BEAM 02-25-2025
- Dividend Yield
- KMT 3.30%
- BEAM N/A
- EPS Growth
- KMT N/A
- BEAM N/A
- EPS
- KMT 1.28
- BEAM N/A
- Revenue
- KMT $2,036,371,000.00
- BEAM $349,643,000.00
- Revenue This Year
- KMT $0.25
- BEAM N/A
- Revenue Next Year
- KMT $2.49
- BEAM $10.82
- P/E Ratio
- KMT $18.94
- BEAM N/A
- Revenue Growth
- KMT N/A
- BEAM 328.73
- 52 Week Low
- KMT $22.50
- BEAM $20.84
- 52 Week High
- KMT $32.18
- BEAM $49.50
- Technical
- Relative Strength Index (RSI)
- KMT 41.24
- BEAM 38.04
- Support Level
- KMT $23.69
- BEAM $22.50
- Resistance Level
- KMT $24.65
- BEAM $28.39
- Average True Range (ATR)
- KMT 0.58
- BEAM 1.68
- MACD
- KMT 0.14
- BEAM -0.41
- Stochastic Oscillator
- KMT 65.60
- BEAM 15.05
About KMT Kennametal Inc.
Kennametal Inc is a manufacturer of metalworking tools and wear-resistant engineered components and coatings. The company operates in two business segments; Metal Cutting and Infrastructure. It generates maximum revenue from the Metal Cutting segment. The Metal Cutting segment develops and manufactures high-performance tooling and metal cutting products and services and offers an assortment of standard and custom metal cutting solutions to diverse end markets, including aerospace, general engineering, energy, and transportation. Geographically, it derives maximum revenue from the United States and the rest from Germany, China, Canada, India, Italy, and other countries.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.